Expression of Heat Shock Protein 27 according to Gleason Score and Pathologic Stage of Prostate Cancer

Seung Wook Lee; Eun Kyung Kim; Sang Soo Kim; Hong Sun Uh; Kyung Suk Cha; Tag Keun Yoo

doi:10.4111/kju.2009.50.6.547

Journal List > Korean J Urol > v.50(6) > 1005346

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Lee, Kim, Kim, Uh, Cha, and Yoo: Expression of Heat Shock Protein 27 according to Gleason Score and Pathologic Stage of Prostate Cancer

Original Article

Korean J Urol 2009;50(6):547-552.

Published online: 19 June 2009

DOI: https://doi.org/10.4111/kju.2009.50.6.547

Expression of Heat Shock Protein 27 according to Gleason Score and Pathologic Stage of Prostate Cancer

Seung Wook Lee, Eun Kyung Kim¹, Sang Soo Kim², Hong Sun Uh³, Kyung Suk Cha, Tag Keun Yoo

¹From the Departments of Urology and Pathology, Eulji University School of Urologic Clinic Office, Seoul, Korea

²Natural Science, School of Urologic Clinic Office, Seoul, Korea Korea

³Natural Science, Uh's Urologic Clinic Office, Seoul, Korea Korea

Correspondence to: Tag Keun Yoo Department of Urology, Eulji Hospital, Eulji University School of Medicine, 14, Hangeulbiseok-gil, Nowon-gu, Seoul 139-711, Korea TEL: 02-970-8305 FAX: 02-970-8349 E-mail: ytk5202@eulji.ac.kr

Received 2 April 2009 Accepted 22 May 2009

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose:

Heat shock protein 27 (HSP27) is induced by heat shock and other pathophysiologic stresses. We examined the relationship between HSP27 expression and Gleason score and pathologic stage of prostate cancer.

Materials and Methods:

Fifty-three men were treated by radical prostatectomy for prostate cancer diagnosed from May 2004 to April 2007. Prostate tissues (n=53) were obtained from radical prostatectomy specimens of prostate cancer. The overall percentage of cancer cells showing staining (0% to 100%) was indicated by visual scoring. Specimens were graded from ＋1 to ＋3 intensity representing the range of staining area, for which below 5% is ＋1 grade, 5-50% is ＋2 grade, over 50% is ＋3 grade and focal reaction is ＋0.5 grade.

Results:

An HSP27-positive reaction was seen in 2 of 11 cases (18.2%) with a Gleason score of 4-6, 11 of 19 cases (57.9%) with a Gleason score 7, 6 of 10 cases (60.0%) with a Gleason score 8, 12 of 13 cases (92.3%) with a Gleason score of 9 (p=0.001); the mean HSP27 reaction scores were 0.27, 0.86, 0.83, and 1.54 respectively (p=0.006). An HSP27-positive reaction was seen in 17 of 37 cases (46.0%) with pathologic stage T2, 10 of 12 cases (83.3%) with pathologic stage T3, and 4 of 4 cases (100%) with pathologic stage T4 (p=0.0032); the mean HSP27 reaction scores were 0.64, 1.17, and 2, respectively (p=0.007). HSP27 expression was not statistically significant according to age.

Conclusions:

There is correlation between HSP27 expression and Gleason score, pathologic stage of prostate cancer.

Keywords: HSP27 heat-shock proteins, Prostatic neoplasms

REFERENCES

1.Atkins D., Lichtenfels R., Seliger B. Heat shock proteins in renal cell carcinomas. Contrib Nephrol. 2005. 148:35–56.

2.Gelb AB. Renal cell carcinoma: current prognostic factors. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997. 80:981–6.

3.Lichtenfels R., Kellner R., Bukur J., Beck J., Brenner W., Ackermann A, et al. Heat shock protein expression and anti-heat shock protein reactivity in renal cell carcinoma. Proteomics. 2002. 2:561–70.

4.Storm FK., Mahvi DM., Gilchrist KW. Heat shock protein 27 overexpression in breast cancer lymph node metastasis. Ann Surg Oncol. 1996. 3:570–3.

5.Arts HJ., Hollema H., Lemstra W., Willemse PH., De Vries EG., Kampinga HH, et al. Heat-shock-protein-27 (hsp27) expression in ovarian carcinoma: relation in response to chemotherapy and prognosis. Int J Cancer. 1999. 84:234–8.

6.Mese H., Sasaki A., Nakayama S., Yoshioka N., Yoshihama Y., Kishimoto K, et al. Prognostic significance of heat shock protein 27 (HSP27) in patients with oral squamous cell carcinoma. Oncol Rep. 2002. 9:341–4.

7.Rocchi P., So A., Kojima S., Signaevsky M., Beraldi E., Fazli L, et al. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res. 2004. 64:6595–602.

8.Youm YH., Kim S., Bahk YY., Yoo TK. Proteomic analysis of androgen-independent growth in low and high passage human LNCaP prostatic adenocarcinoma cells. BMB Rep. 2008. 41:722–7.

9.Sarto C., Valsecchi C., Magni F., Tremolada L., Arizzi C., Cor-dani N, et al. Expression of heat shock protein 27 in human renal cell carcinoma. Proteomics. 2004. 4:2252–60.

10.Concannon CG., Orrenius S., Samali A. HSP27 inhibits cytochrome c-mediated caspase activation by sequestering both pro-caspase-3 and cytochrome c. Gene Expr. 2001. 9:195–201.

11.Erkizan O., Kirkali G., Yorukoglu K., Kirkali Z. Significance of heat shock protein-27 expression in patients with renal cell carcinoma. Urology. 2004. 64:474–8.

12.Oki Y., Younes A. Heat shock protein-based cancer vaccines. Expert Rev Vaccines. 2004. 3:403–11.

13.Hoos A., Levey DL. Vaccination with heat shock protein-peptide complexes: from basic science to clinical applications. Expert Rev Vaccines. 2003. 2:369–79.

14.Miyake H., Muramaki M., Kurahashi T., Takenaka A., Fujisawa M. Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. Urol Oncol. 2008. Epub ahead of print.

15.Rocchi P., Beraldi E., Ettinger S., Fazli L., Vessella RL., Nelson C, et al. Increased HSP27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Res. 2005. 65:11083–93.

16.Teimourian S., Jalal R., Sohrabpour M., Goliaei B. Down-regulation of HSP27 radiosensitizes human prostate cancer cells. Int J Urol. 2006. 13:1221–5.

17.Choi CJ., Park DS., Oh KH. Prognostic significance of heat shock protein 70 expression in bladder tumor. Korean J Urol. 1997. 38:951–6.

18.Yoon GS. Expression of heat shock protein 27 and apoptosis in renal cell caecinomas. Korean J Pathol. 2006. 40:39–45.

19.Lee H., Kwon TK., Park JW., Lee KS. The study about expression and regulation mechanism of heat shock protein 70 by arisostatins A in Caki cell line of renal cell carcinoma. Korean J Urol. 2005. 46:181–9.

20.Jeong WJ., Song KH., Kim KJ. Expression of heat shock protein 70 in ipsilateral rat kidney with unilateral partial ureteral obstruction. Korean J Urol. 2002. 43:1065–9.

21.Park SH., Park K., Park YI. Effects of temperature change on heat shock protein 70 expression in rat testes. Korean J Urol. 2003. 44:186–91.

Fig. 1

HSP27 expression in prostate tissues (A: no reaction-0, B: local reaction-0.5, C: below 5% reaction-1, D: 5-50% reaction-2, E: above 50% reaction-3, F: no reaction in BPH). Specimens were graded from 0 to ＋3 intensity representing the range from no staining to heavy staining by visual scoring. HSP27: heat shock protein 27, BPH: benign prostatic hyperplasia (Immunohistochemical stain, x200).

Table 1.

Patient characteristics (n=53)

Variable
Age (years)	67.5 (±16.2)
Gleason score	No. of patients (%)
4-6	11 (21)
7	19 (36)
8	10 (19)
9	13 (24)
T stage
T2	37 (69)
T3	12 (23)
T4	4 (8)
Lymph node metastasis
No	49 (92)
Yes	4 (8)
Distant metastasis
No	53 (100)
Yes	0 (0)

Table 2.

HSP27 expression and clinicopathological data of prostate cancer

Variables	No. of	HSP27
Variables	patients (%)	(－) (＋)	p-value
Gleason score
4-6	11 (21)	9 (81.8) 2 (18.2)	0.001
7	19 (36)	8 (42.1) 11 (57.9)
8	10 (19)	4 (40.0) 6 (60)
9	13 (24)	1 (7.7) 12 (92.3)
Tumor stage
T2	37 (69)	10 (54.0) 17 (46.0)	0.0032
T3	12 (23)	2 (16.7) 10 (83.3)
T4	4 (8)	0 (0) 4 (100)

HSP27: heat shock protein 27

Table 3.

Average reaction score of HSP27 expression according to clinicopathological data of prostate cancer

Variables	No. of patients (%)	Average reaction score	p-value
Gleason score
4-6	11 (21)	0.27	0.006
7	19 (36)	0.86
8	10 (19)	0.83
9^a	13 (24)	1.54
Tumor stage
T2	37 (69)	0.64	0.007
T3	12 (23)	1.17
T4^b	4 (8)	2.00

HSP27: heat shock protein 27,

^a : vs. Gleason score 4-6, p＜0.05,

^b : vs. Tumor stage T2, p＜0.05

TOOLS

Similar articles